Veracyte, Inc. (NASDAQ:VCYT) is set to announce its quarterly earnings on February 25, 2026, after the market closes. Analysts predict an earnings per share (EPS) of $0.41 and revenue of approximately $135.8 million. Veracyte specializes in genomic diagnostics, offering tests like Decipher and Afirma, which are key drivers of its revenue growth. The company competes with other diagnostic firms in the healthcare sector.
In the previous quarter, Veracyte's adjusted EPS of $0.51 surpassed the Zacks Consensus Estimate by 59.38%. The company has consistently exceeded earnings estimates over the last four quarters, with an average surprise of 45.12%. For the upcoming Q4 results, the Zacks Consensus Estimate for EPS is $0.41, reflecting a 13.9% increase from the previous year. Earnings estimates have been revised upwards by 2% ahead of the announcement.
Veracyte's financial metrics reveal a high valuation, with a price-to-earnings (P/E) ratio of approximately 94.73. This suggests that investors are willing to pay a premium for the company's earnings. The price-to-sales ratio of about 5.82 indicates that investors are paying over five times the company's sales per share. Additionally, the enterprise value to sales ratio is around 5.27, while the enterprise value to operating cash flow ratio is approximately 24.10.
The company's earnings yield is about 1.06%. Veracyte maintains a low debt-to-equity ratio of 0.03, indicating minimal reliance on debt financing. This is complemented by a strong current ratio of 6.23, suggesting robust liquidity and the ability to cover short-term liabilities. These financial metrics highlight Veracyte's solid financial position and potential for future growth.
